paclitaxel

A new paradigm in the treatment of in-stent restenosis?

Original title:&nbsp;ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents&nbsp;Reference:&nbsp;Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or<a href="https://solaci.org/en/2012/11/11/a-new-paradigm-in-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>

Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery

Original title:&nbsp;Drug-Eluting Balloon for Treatment of Superficial Femoral Artery In-Stent Restenosis&nbsp;Reference:&nbsp;Eugenio Stabile et al. Journal of the American College of Cardiology 60:1739&ndash;42 (2012) Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery&nbsp; This prospective registry included 39 patients who received Paclitaxel-Eluting Balloon Angioplasty, (IN.PACT, Medtronic, Minneapolis, Minnesota), for in-stent<a href="https://solaci.org/en/2012/11/09/drug-eluting-balloon-a-valid-alternative-to-treat-in-stent-restenosis-in-the-superficial-femoral-artery/" title="Read more" >...</a>

Diabetics with multivessel, must keep waiting.

Original title:&nbsp;Strategies for Multivessel Revascularization in Patients with Diabetes. The FREEDOM Trial.&nbsp;Reference:&nbsp;Michael E. Farkouh et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585 This study was designed to determine the best revascularization strategy in diabetic patients with multivessel using current techniques of angioplasty (PCI) and surgery (CABG). Randomized 1:1 diabetic patients with injuries &gt; 70%<a href="https://solaci.org/en/2012/11/08/diabetics-with-multivessel-must-keep-waiting/" title="Read more" >...</a>

Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents

The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,<a href="https://solaci.org/en/2012/10/01/drug-eluting-stents-device-without-polymers-overcomes-limitations-of-first-generations-stents/" title="Read more" >...</a>

Top